| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_285d84c590a5862a0fd7d2bf29381f6e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d683c6d6e46f3f2967f4541c400ca15c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_3f49d4443ce9731528042e85e4cb435e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2bf162526d6550726fe12fab2a4b908b |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K48-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2510-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2803 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K48-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0647
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2803
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-28 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K48-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-17
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-12 |
| filingDate |
2019-11-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_539502c297ec236718ac54d3848faa72
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_abe9345ec25811b1f2e38d2ccc5d6567
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3382b7907a2d6793875f4e444db203e7 |
| publicationDate |
2020-06-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2020112870-A1 |
| titleOfInvention |
Genetically modified hspcs resistant to ablation regime |
| abstract |
The invention provides genetically modified hematopoietic stem or progenitor cells (HSPCs) and methods of using the HSPCs in stem cell replacement therapy. The HSPCs are genetically modified to express a receptor conferring a selective advantage on the introduced cells relative to endogenous HSPCs or a control HSPCs without the modification. The presence of such a receptor provides resistance to an immunotherapy regime used for eliminating endogenous HSPCs. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11591381-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2022173861-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2023069961-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11208482-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11041022-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11459372-B2 |
| priorityDate |
2018-11-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |